Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results
November 7, 2018 4:01 PM ESTWASHINGTON, Nov. 7, 2018 /PRNewswire/ --Â Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2018.
Key Highlights:
Vanda reiterates 2018 net product sales guidance of $180 million to $200 million. Total net product sales from HETLIOZ® and Fanapt® were $49.1 million during the third quarter of 2018, a 4% increase compared to $47.4 million in the second quarter of 2018 and a 19% increase compared to $41.3 million in the third quarter of 2017.HETLIOZ® (tasimelteon)
HETLIOZ® net product sales were $29.9 million in... More